newsfilter
← Latest News
Business Wire·

AstraZeneca results: 9M and Q3 2026

Continued strong commercial performance and 12 positive Phase III programme readouts in the year to date AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 %